aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis R Fan, G Papatheodoridis, J Sun, H Innes, H Toyoda, Q Xie, S Mo, ... Journal of Hepatology 73 (6), 1368-1378, 2020 | 208 | 2020 |
Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause‐specific outcomes HA Innes, SA McDonald, JF Dillon, S Allen, PC Hayes, D Goldberg, ... Hepatology 62 (2), 355-364, 2015 | 142 | 2015 |
The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: role of the treatment regimen H Innes, ST Barclay, PC Hayes, A Fraser, JF Dillon, A Stanley, A Bathgate, ... Journal of hepatology 68 (4), 646-654, 2018 | 117 | 2018 |
Factors associated with spontaneous clearance of chronic hepatitis C virus infection N Bulteel, PP Sarathy, E Forrest, AJ Stanley, H Innes, PR Mills, H Valerio, ... Journal of hepatology 65 (2), 266-272, 2016 | 108 | 2016 |
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs HJ Cordell, JJ Fryett, K Ueno, R Darlay, Y Aiba, Y Hitomi, M Kawashima, ... Journal of hepatology 75 (3), 572-581, 2021 | 91 | 2021 |
Quantifying the fraction of cirrhosis attributable to alcohol among chronic hepatitis C virus patients: implications for treatment cost‐effectiveness HA Innes, SJ Hutchinson, S Barclay, E Cadzow, JF Dillon, A Fraser, ... Hepatology 57 (2), 451-460, 2013 | 85 | 2013 |
Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a … A Radley, M De Bruin, SK Inglis, PT Donnan, A Hapca, ST Barclay, ... The lancet Gastroenterology & hepatology 5 (9), 809-818, 2020 | 76 | 2020 |
Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population H Innes, S McDonald, P Hayes, JF Dillon, S Allen, D Goldberg, PR Mills, ... Journal of Hepatology 66 (1), 19-27, 2017 | 71 | 2017 |
A matched comparison study of hepatitis C treatment outcomes in the prison and community setting, and an analysis of the impact of prison release or transfer during therapy EJ Aspinall, W Mitchell, J Schofield, A Cairns, S Lamond, P Bramley, ... Journal of viral hepatitis 23 (12), 1009-1016, 2016 | 67 | 2016 |
Hepatitis C reinfection following treatment induced viral clearance among people who have injected drugs A Weir, A McLeod, H Innes, H Valerio, EJ Aspinall, DJ Goldberg, ... Drug and alcohol dependence 165, 53-60, 2016 | 54 | 2016 |
The management of chronic hepatitis B in the immunocompromised patient: recommendations from a single topic meeting S Barclay, S Pol, D Mutimer, Y Benhamou, PR Mills, PC Hayes, ... Journal of Clinical Virology 41 (4), 243-254, 2008 | 51 | 2008 |
2014 UK consensus guidelines–hepatitis C management and direct‐acting anti‐viral therapy MH Miller, K Agarwal, A Austin, A Brown, ST Barclay, P Dundas, ... Alimentary pharmacology & therapeutics 39 (12), 1363-1375, 2014 | 47 | 2014 |
Uptake of hepatitis C specialist services and treatment following diagnosis by dried blood spot in Scotland G McAllister, H Innes, A Mcleod, JF Dillon, PC Hayes, R Fox, ST Barclay, ... Journal of Clinical Virology 61 (3), 359-364, 2014 | 46 | 2014 |
Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British … S McPherson, MJ Armstrong, JF Cobbold, L Corless, QM Anstee, ... The lancet Gastroenterology & hepatology 7 (8), 755-769, 2022 | 44 | 2022 |
Administration of end-of-life drugs by family caregivers during covid-19 pandemic B Bowers, K Pollock, S Barclay Bmj 369, 2020 | 41 | 2020 |
Erratum to ‘The management of chronic hepatitis B in the immunocompromised patient: Recommendations from a single topic meeting’[J. Clin. Virol. 41 (4) 2008 243–254] S Barclay, S Pol, D Mutimer, Y Benhamou, PR Mills, PC Hayes, ... Journal of Clinical Virology 42 (1), 104-115, 2008 | 41 | 2008 |
Greater transplant-free survival in patients receiving obeticholic acid for primary biliary cholangitis in a clinical trial setting compared to real-world external controls CFM Perez, H Fisher, S Hiu, D Kareithi, F Adekunle, T Mayne, E Malecha, ... Gastroenterology 163 (6), 1630-1642. e3, 2022 | 39 | 2022 |
Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs A Yeung, NE Palmateer, JF Dillon, SA McDonald, S Smith, S Barclay, ... Journal of Hepatology 76 (3), 549-557, 2022 | 38 | 2022 |
Broad anti-hepatitis C virus (HCV) antibody responses are associated with improved clinical disease parameters in chronic HCV infection RE Swann, VM Cowton, MW Robinson, SJ Cole, ST Barclay, PR Mills, ... Journal of virology 90 (9), 4530-4543, 2016 | 38 | 2016 |
Real‐world impact following initiation of interferon‐free hepatitis C regimens on liver‐related outcomes and all‐cause mortality among patients with compensated cirrhosis SA McDonald, KG Pollock, ST Barclay, DJ Goldberg, A Bathgate, ... Journal of viral hepatitis 27 (3), 270-280, 2020 | 35 | 2020 |